Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Tirzepatide showed a 38% reduction in the risk of heart failure outcomes, assessed as a composite endpoint, compared to placebo. Risk of hospitalization for heart failure was reduced by 56%.

Worsening heart failure events occurred in 29 patients (8.0%) in the tirzepatide group compared to 52 (14.2%) in the placebo group, representing a 46% reduction in risk for those taking tirzepatide.

On the primary endpoints of the study, combined cardiovascular mortality and worsening heart failure events (α = 0.04) were determined in 36 patients (9.9%) in the tirzepatide group, whereas in ...

Tirzepatide showed a 38% reduction in the risk of heart failure outcomes, assessed as a composite endpoint, compared to placebo. Risk of hospitalization for heart failure was reduced by 56%.

Worsening heart failure events occurred in 29 patients (8.0%) in the tirzepatide group compared to 52 (14.2%) in the placebo group, representing a 46% reduction in risk for those taking tirzepatide.

Worsening heart failure events occurred in 8.0% and 14.2% of patients in the tirzepatide and placebo groups, respectively (hazard ratio, 0.54; 95 percent confidence interval, 0.34 to 0.85 ...

Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...

Update: Adds latest share movement. Tirzepatide, currently marketed by Eli Lilly (NYSE:LLY) as Mounjaro and Zepbound for, respectively, diabetes and weight loss, reduced the risk of heart failure ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

How Tirzepatide Enhances Heart Health The clinical trial, detailed on ClinicalTrials.gov, was a randomized, double-blind, placebo-controlled study that involved 731 participants aged 40 and older ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk of worsening heart failure events in adults with ...